Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen reports PREPARE data

AMGN said late Friday that interim data from the Phase III PREPARE trial in 733 patients showed that Aranesp darbepoetin alfa plus preoperative chemotherapy resulted

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE